Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

1.

The Role of Neuron-specific Enolase (NSE) and Thimidine Kinase (TK) Levels in Prediction of Efficacy of EGFR-TKIs in Patients with Advanced-stage NSCLC.

Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, Topolcan O.

Anticancer Res. 2014 Sep;34(9):5193-8.

PMID:
25202114
[PubMed - in process]
2.

Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.

Fiala O, Pesek M, Finek J, Krakorova G, Benesova L, Minarik M.

Tumori. 2014 May-Jun;100(3):e70-3. doi: 10.1700/1578.17234.

PMID:
25076254
[PubMed - in process]
3.

The impact of PET/CT scanning on the size of target volumes, radiation exposure of organs at risk, TCP and NTCP, in the radiotherapy planning of non-small cell lung cancer.

Vojtíšek R, Mužík J, Slampa P, Budíková M, Hejsek J, Smolák P, Ferda J, Fínek J.

Rep Pract Oncol Radiother. 2013 Oct 17;19(3):182-90. doi: 10.1016/j.rpor.2013.09.006. eCollection 2014 May.

PMID:
24944819
[PubMed]
4.

Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.

Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, Topolcan O.

Anticancer Res. 2014 Jun;34(6):3205-10.

PMID:
24922695
[PubMed - indexed for MEDLINE]
5.

[On the importance of standardization in the assessment of population-based cancer patient survival in the Czech Republic -  methodology and results from the Czech National Cancer Registry].

Uher M, Pavlík T, Májek O, Mužík J, Büchler T, Abrahámová J, Vyzula R, Fínek J, Vorlíček J, Dušek L.

Klin Onkol. 2014;27(2):127-35. Czech.

PMID:
24739049
[PubMed - in process]
6.

Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry.

Slavicek L, Pavlik T, Tomasek J, Bortlicek Z, Buchler T, Melichar B, Vyzula R, Prausova J, Finek J, Majek O, Dusek L.

BMC Gastroenterol. 2014 Mar 25;14:53. doi: 10.1186/1471-230X-14-53.

PMID:
24666582
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

[MRI based 3D brachytherapy planning of the cervical cancer -  our experiences with the use of the uterovaginal Vienna Ring MR CT applicator].

Vojtíšek R, Mouryc F, Cechová D, Ciprová R, Ferda J, Fínek J.

Klin Onkol. 2014;27(1):45-51. Czech.

PMID:
24635437
[PubMed - in process]
8.

[Chylous ascites as a serious complication of the neuroendocrine tumor of ileum -  case report].

Matějka VM, Fiala O, Tupý R, Holubec L, Fínek J.

Klin Onkol. 2013;26(5):358-61. Czech.

PMID:
24107160
[PubMed - in process]
9.

[Polyneuropathic pain therapy with a patient suffering from generalized castrate- resistant prostate cancer -  clinical case report].

Holubec L, Mrázková P, Matějka VM, Fiala O, Fínek J.

Klin Onkol. 2013;26(5):354-7. Czech.

PMID:
24107159
[PubMed - in process]
10.

Erlotinib in the treatment of advanced squamous cell NSCLC.

Fiala O, Pesek M, Finek J, Krejci J, Havel L, Hrnciarik M, Salajka F, Bortlicek Z, Benesova L, Minarik M.

Neoplasma. 2013;60(6):676-82. doi: 10.4149/neo_2013_086.

PMID:
23906302
[PubMed - indexed for MEDLINE]
11.

Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence.

Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z, Minarik M.

Anticancer Res. 2013 Aug;33(8):3397-402.

PMID:
23898110
[PubMed - indexed for MEDLINE]
12.

Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.

Anghel R, Bachmann A, Bekşac M, Brodowicz T, Finek J, Komadina R, Krzemieniecki K, Lang I, Marencak J, von Moos R, Pecherstorfer M, Rordorf T, Vrbanec D, Zielinski C; American Society of Clinical Oncology; National Comprehensive Cancer Network.

Wien Klin Wochenschr. 2013 Aug;125(15-16):439-47. doi: 10.1007/s00508-013-0385-4. Epub 2013 Jul 6.

PMID:
23832237
[PubMed - indexed for MEDLINE]
13.

A role of multifactorial evaluation of prostatic 3T MRI in patients with elevated prostatic-specific antigen levels: prospective comparison with ultrasound-guided transrectal biopsy.

Ferda J, Kastner J, Hora M, Hes O, Fínek J, Topolčan O, Kreuzberg B.

Anticancer Res. 2013 Jun;33(6):2791-5.

PMID:
23749943
[PubMed - indexed for MEDLINE]
14.

18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation.

Ferda J, Ferdova E, Hora M, Hes O, Finek J, Topolcan O, Kreuzberg B.

Anticancer Res. 2013 Jun;33(6):2665-72.

PMID:
23749925
[PubMed - indexed for MEDLINE]
15.

[Another approach to targeted therapy of patients with metastatic renal carcinoma with progression in treatment with pazopanib:expert assessment by the Czech Cooperative Group for Metastatic Renal Carcinoma].

Büchler T, Finek J, Hájek J, Kocák I, Kubácková K, Lakomý R, Melichar B, Petruzelka L, Poprach A, Siffnerová M, Tomásek J, Vyzula R, Zemanová M; Cezkou Kooperativní Skupinu pro Metastický Renální Karcinom.

Klin Onkol. 2013;26(1):55-7. Czech. No abstract available.

PMID:
23607143
[PubMed - indexed for MEDLINE]
16.

Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC.

Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z, Minarik M.

Neoplasma. 2013;60(4):425-31. doi: 10.4149/neo_2013_055.

PMID:
23581415
[PubMed - indexed for MEDLINE]
17.

Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.

Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z, Minarik M.

Anticancer Res. 2013 Apr;33(4):1705-11.

PMID:
23564819
[PubMed - indexed for MEDLINE]
18.

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M.

Cancer Genet. 2013 Jan-Feb;206(1-2):26-31. doi: 10.1016/j.cancergen.2012.12.003. Epub 2013 Jan 10.

PMID:
23313110
[PubMed - indexed for MEDLINE]
19.

Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy.

Fiala O, Pesek M, Finek J, Krejci J, Bortlicek Z, Benesova L, Minarik M.

Neoplasma. 2013;60(2):129-34.

PMID:
23259780
[PubMed - indexed for MEDLINE]
20.

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C; TRIO/BCIRG 001 investigators.

Lancet Oncol. 2013 Jan;14(1):72-80. doi: 10.1016/S1470-2045(12)70525-9. Epub 2012 Dec 12.

PMID:
23246022
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk